Which has better valuation and earnings, OABI or OPRX?

OptimizeRx has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $28.94M 12.51 -$64.78M -$0.46 N/A OptimizeRx $109.43M 0.85 $5.13M $0.35 14.14

Is OABI or OPRX more profitable?

OptimizeRx has a net margin of 6.37% compared to OmniAb's net margin of -187.59%. OptimizeRx's return on equity of 10.86% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -187.59% -20.31% -18.10% OptimizeRx 6.37% 10.86% 7.93%

Does the media favor OABI or OPRX?

In the previous week, OmniAb and OmniAb both had 2 articles in the media. OmniAb's average media sentiment score of 0.93 beat OptimizeRx's score of 0.62 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TSSI or OPRX?

TSS has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than TSS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TSS $245.72M 1.59 $15.12M $0.49 28.43 OptimizeRx $109.43M 0.85 $5.13M $0.35 14.14

Is TSSI or OPRX more profitable?

TSS has a net margin of 7.14% compared to OptimizeRx's net margin of 6.37%. TSS's return on equity of 25.27% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets TSS 7.14% 25.27% 8.97% OptimizeRx 6.37% 10.86% 7.93%

Does the media favor TSSI or OPRX?

In the previous week, TSS had 6 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for TSS and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.62 beat TSS's score of 0.03 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TSS 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, YEXT or OPRX?

Yext has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Yext, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Yext $446.58M 0.85 $37.87M $0.06 63.42 OptimizeRx $109.43M 0.85 $5.13M $0.35 14.14

Is YEXT or OPRX more profitable?

Yext has a net margin of 8.48% compared to OptimizeRx's net margin of 6.37%. Yext's return on equity of 29.61% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets Yext 8.48% 29.61% 7.59% OptimizeRx 6.37% 10.86% 7.93%

Does the media refer more to YEXT or OPRX?

In the previous week, Yext had 8 more articles in the media than OptimizeRx. MarketBeat recorded 10 mentions for Yext and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.62 beat Yext's score of 0.35 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yext 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, OPRX or PPHC?

OptimizeRx has higher earnings, but lower revenue than Public Policy. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 0.85 $5.13M $0.35 14.14 Public Policy $197.35M 1.52 N/A N/A N/A

Does the media refer more to OPRX or PPHC?

In the previous week, Public Policy had 1 more articles in the media than OptimizeRx. MarketBeat recorded 3 mentions for Public Policy and 2 mentions for OptimizeRx. Public Policy's average media sentiment score of 0.63 beat OptimizeRx's score of 0.62 indicating that Public Policy is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Public Policy 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SOHU or OPRX?

Sohu.com has higher revenue and earnings than OptimizeRx. Sohu.com is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sohu.com $584.33M 0.60 $394.10M $7.84 1.73 OptimizeRx $109.43M 0.85 $5.13M $0.35 14.14

Is SOHU or OPRX more profitable?

Sohu.com has a net margin of 35.19% compared to OptimizeRx's net margin of 6.37%. Sohu.com's return on equity of 20.92% beat OptimizeRx's return on equity. Company Net Margins Return on Equity Return on Assets Sohu.com 35.19% 20.92% 14.76% OptimizeRx 6.37% 10.86% 7.93%

OptimizeRx (OPRX) Competitors

$4.95 -0.33 (-6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.96 +0.01 (+0.30%)

As of 04:10 PM Eastern

Compare

OPRX vs. OABI, TSSI, YEXT, PPHC, and SOHU

Should you buy OptimizeRx stock or one of its competitors? MarketBeat compares OptimizeRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OptimizeRx include OmniAb (OABI), TSS (TSSI), Yext (YEXT), Public Policy (PPHC), and Sohu.com (SOHU). These companies are all part of the "business services" industry.

How does OptimizeRx compare to OmniAb?

OmniAb (NASDAQ:OABI) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

OmniAb presently has a consensus price target of $3.00, indicating a potential upside of 20.00%. OptimizeRx has a consensus price target of $13.43, indicating a potential upside of 171.28%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than OmniAb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

OmniAb has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

OptimizeRx has a net margin of 6.37% compared to OmniAb's net margin of -187.59%. OptimizeRx's return on equity of 10.86% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-187.59%	-20.31%	-18.10%
OptimizeRx	6.37%	10.86%	7.93%

OptimizeRx has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$28.94M	12.51	-$64.78M	-$0.46	N/A
OptimizeRx	$109.43M	0.85	$5.13M	$0.35	14.14

72.1% of OmniAb shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Comparatively, 5.6% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, OmniAb and OmniAb both had 2 articles in the media. OmniAb's average media sentiment score of 0.93 beat OptimizeRx's score of 0.62 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OptimizeRx beats OmniAb on 12 of the 15 factors compared between the two stocks.

How does OptimizeRx compare to TSS?

TSS (NASDAQ:TSSI) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

TSS has a net margin of 7.14% compared to OptimizeRx's net margin of 6.37%. TSS's return on equity of 25.27% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TSS	7.14%	25.27%	8.97%
OptimizeRx	6.37%	10.86%	7.93%

TSS has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

76.5% of OptimizeRx shares are held by institutional investors. 16.0% of TSS shares are held by insiders. Comparatively, 5.6% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, TSS had 6 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for TSS and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.62 beat TSS's score of 0.03 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TSS	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TSS has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than TSS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TSS	$245.72M	1.59	$15.12M	$0.49	28.43
OptimizeRx	$109.43M	0.85	$5.13M	$0.35	14.14

TSS currently has a consensus target price of $17.17, suggesting a potential upside of 23.24%. OptimizeRx has a consensus target price of $13.43, suggesting a potential upside of 171.28%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than TSS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TSS	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

TSS beats OptimizeRx on 11 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Yext?

Yext (NYSE:YEXT) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Yext has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Yext, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yext	$446.58M	0.85	$37.87M	$0.06	63.42
OptimizeRx	$109.43M	0.85	$5.13M	$0.35	14.14

Yext has a net margin of 8.48% compared to OptimizeRx's net margin of 6.37%. Yext's return on equity of 29.61% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yext	8.48%	29.61%	7.59%
OptimizeRx	6.37%	10.86%	7.93%

Yext has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

71.0% of Yext shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 7.8% of Yext shares are owned by company insiders. Comparatively, 5.6% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Yext currently has a consensus target price of $7.50, indicating a potential upside of 97.11%. OptimizeRx has a consensus target price of $13.43, indicating a potential upside of 171.28%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than Yext.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yext	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Yext had 8 more articles in the media than OptimizeRx. MarketBeat recorded 10 mentions for Yext and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.62 beat Yext's score of 0.35 indicating that OptimizeRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yext	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Yext beats OptimizeRx on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Public Policy?

OptimizeRx (NASDAQ:OPRX) and Public Policy (NASDAQ:PPHC) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

76.5% of OptimizeRx shares are owned by institutional investors. 5.6% of OptimizeRx shares are owned by company insiders. Comparatively, 14.6% of Public Policy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Public Policy had 1 more articles in the media than OptimizeRx. MarketBeat recorded 3 mentions for Public Policy and 2 mentions for OptimizeRx. Public Policy's average media sentiment score of 0.63 beat OptimizeRx's score of 0.62 indicating that Public Policy is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Public Policy	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has higher earnings, but lower revenue than Public Policy.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	0.85	$5.13M	$0.35	14.14
Public Policy	$197.35M	1.52	N/A	N/A	N/A

OptimizeRx presently has a consensus price target of $13.43, suggesting a potential upside of 171.28%. Public Policy has a consensus price target of $17.00, suggesting a potential upside of 66.34%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Public Policy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Public Policy	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

OptimizeRx has a net margin of 6.37% compared to Public Policy's net margin of 0.00%. OptimizeRx's return on equity of 10.86% beat Public Policy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	6.37%	10.86%	7.93%
Public Policy	N/A	N/A	N/A

Summary

OptimizeRx beats Public Policy on 7 of the 12 factors compared between the two stocks.

How does OptimizeRx compare to Sohu.com?

Sohu.com (NASDAQ:SOHU) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

33.0% of Sohu.com shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 21.1% of Sohu.com shares are held by insiders. Comparatively, 5.6% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sohu.com has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, OptimizeRx had 1 more articles in the media than Sohu.com. MarketBeat recorded 2 mentions for OptimizeRx and 1 mentions for Sohu.com. Sohu.com's average media sentiment score of 1.89 beat OptimizeRx's score of 0.62 indicating that Sohu.com is being referred to more favorably in the media.

Company	Overall Sentiment
Sohu.com	Very Positive
OptimizeRx	Positive

Sohu.com currently has a consensus target price of $19.00, indicating a potential upside of 40.22%. OptimizeRx has a consensus target price of $13.43, indicating a potential upside of 171.28%. Given OptimizeRx's higher probable upside, analysts plainly believe OptimizeRx is more favorable than Sohu.com.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sohu.com	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Sohu.com has a net margin of 35.19% compared to OptimizeRx's net margin of 6.37%. Sohu.com's return on equity of 20.92% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sohu.com	35.19%	20.92%	14.76%
OptimizeRx	6.37%	10.86%	7.93%

Sohu.com has higher revenue and earnings than OptimizeRx. Sohu.com is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sohu.com	$584.33M	0.60	$394.10M	$7.84	1.73
OptimizeRx	$109.43M	0.85	$5.13M	$0.35	14.14

Summary

Sohu.com beats OptimizeRx on 9 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPRX vs. The Competition

Export

Metric	OptimizeRx	COMP Industry	Computer Sector	NASDAQ Exchange
Market Cap	$92.86M	$152.28B	$40.59B	$12.42B
Dividend Yield	N/A	1.86%	3.10%	5.29%
P/E Ratio	14.14	21.43	173.10	24.19
Price / Sales	0.85	141.97	624.91	138.33
Price / Cash	5.47	19.13	51.77	57.88
Price / Book	0.72	30.85	10.09	6.72
Net Income	$5.13M	$5.11B	$1.06B	$337.19M
7 Day Performance	1.43%	3.72%	3.81%	0.48%
1 Month Performance	-26.12%	3.37%	10.98%	5.06%
1 Year Performance	-62.56%	-16.53%	170.16%	34.27%

OptimizeRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPRX OptimizeRx	4.7395 of 5 stars	$4.95 -6.3%	$13.43 +171.3%	-57.2%	$92.86M	$109.43M	14.14	100
OABI OmniAb	2.6133 of 5 stars	$2.60 -1.9%	$3.00 +15.4%	+85.8%	$376.43M	$18.67M	N/A	7
TSSI TSS	2.9665 of 5 stars	$13.26 +10.4%	$17.17 +29.5%	+4.4%	$372.21M	$245.72M	27.06	70	Positive News Insider Trade Gap Up
YEXT Yext	3.3353 of 5 stars	$3.70 +0.5%	$7.50 +102.7%	-36.5%	$370.41M	$446.58M	61.68	1,120	Trending News Earnings Report Gap Down
PPHC Public Policy	4.5156 of 5 stars	$12.37 +7.1%	$17.00 +37.4%	N/A	$363.06M	$197.35M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Competitors